Nothing Special   »   [go: up one dir, main page]

WO2000000179A1 - Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof - Google Patents

Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof Download PDF

Info

Publication number
WO2000000179A1
WO2000000179A1 PCT/KR1999/000341 KR9900341W WO0000179A1 WO 2000000179 A1 WO2000000179 A1 WO 2000000179A1 KR 9900341 W KR9900341 W KR 9900341W WO 0000179 A1 WO0000179 A1 WO 0000179A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
solid dispersed
oil
acid
soluble
Prior art date
Application number
PCT/KR1999/000341
Other languages
French (fr)
Inventor
Beom Jin Lee
Original Assignee
Won Jin Biopharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Won Jin Biopharma Co., Ltd. filed Critical Won Jin Biopharma Co., Ltd.
Priority to AU46556/99A priority Critical patent/AU4655699A/en
Publication of WO2000000179A1 publication Critical patent/WO2000000179A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • the present invention relates to a solid dispersed preparation for poorly water-soluble drugs or biologically active substances. More particularly, this invention relates to a solid dispersed preparation which allows poorly water-soluble drugs to be increased in the uptake efficiency in the gastro-intestinal track and is convenient to make in a pharmaceutical formulation.
  • a good many drugs poorly dissolve in water .
  • these poorly water-soluble drugs have so low solubility and releasing rate in digestive juices as to retard their absorption, resulting the bioavailability decreased.
  • various preparation methods were developed with the aim of solubilizing these poorly water-soluble drugs and increasing their releasing rates. For instance, there have been reported many methods for improving the bioavailability of drugs, including micronization, formation of micelles by use of surfactant, solvent deposition, utilization of dry elixirs, co-precipitation by use of inert water-soluble carriers, solid-dispersion and formation of inclusion complexes using cyclodextrins .
  • the drugs to be administered do not show a constant increase in solubility. Thus, they are problematic in terms of preparation, commercialization, and efficiency.
  • a solid dispersed preparation for poorly water-soluble drugs is prepared by dissolving or dispersing the drugs in an oil, a fatty acid or a mixture thereof, mixing the solution or dispersion in a water-soluble polyol matrix and drying the mixture.
  • Fig. 1 is a graph in which the plasma concentration of cyclosporine is plotted against the times after administrating the solid dispersed preparations of the present invention (closed rectangle and closed triangle) and a commercially available preparation (Neoral, closed lozenge) ;
  • Fig. 2 is a graph in which the plasma concentration of aceclofenac is plotted against the times after orally administrating aceclofenac powder (closed circle) and the solid dispersed preparation of the present invention (open circle, oleic acid 5%) to rats;
  • Fig. 3 is a graph in which the plasma concentration of cyclosporine is plotted against the times after administrating the solid dispersed preparation of the present invention (closed circle, capsule containing 100 mg of the preparation) and a commercially available preparation (open circle, Airtal capsule 100 mg ) to bealgle dogs;
  • Fig. 4 is a graph in which the plasma concentration of aceclofenac is plotted against the times after orally administrating the solid dispersed preparation of the present invention (closed circle, capsule containing 100 mg of the preparation) and a commercially available preparation (open circle, Airtal capsule 100 mg) to humans; and
  • Fig. 5 is a graph in which the plasma concentration of cisapride is plotted against the times after orally administrating the solid granular preparations of the present invention (open circle, bead 10 mg) and a commercially available preparation (closed circle, prepulsid 10 mg) to humans.
  • a solid dispersed preparation for poorly water- soluble drugs which is prepared by dispersing or dissolving the drugs in an oil, a fatty acid or a mixture thereof, incorporating the dispersion or solution into a water-soluble polymer matrix and drying this mixture.
  • this invention provides two types of fomulation, i.e., the solid powdery preparation and the solid granular preparation.
  • the preparation method of the solid dispersed powders comprises the following steps; Dissolving or dispersing the poorly water-soluble drugs in an oil, a fatty acid or the mixture thereof; mixing with the water-soluble polymer matrix; drying the mixture; and grinding the pellet into powders .
  • the preparation method of the solid dispersed granules comprises the following steps; Dissolving or dispersing the poorly water-soluble drugs in an oil, a fatty acid or the mixture thereof; mixing with the water-soluble polymer matrix; spraying onto a pharmaceutically acceptable nucleus, resulting the granules.
  • the pharmaceutically acceptable nucleus may be a sugar sphere.
  • the solid dispersed powdery preparation or the solid dispersed granular preparation of this invention can be formulated into the pharmaceutically acceptable medicines for internal use such as powders, granules, tablets and capsules .
  • the word “solid dispersed preparation” means “solid dispersed powdery preparation", “solid dispersed granular preparation” or the both.
  • the oil, the fatty acid or the mixture thereof may be used alone or in a form of an emulsion or microemuls on inclusive of itself.
  • a surfactant may be added together .
  • the water-soluble polymer matrix may be used alone or in combination with another water-soluble matrix.
  • Illustrative examples of the oil that can be used in the preparation of the present invention include lipid additives, such as ⁇ -bisabolol, stearyl glycerrhetmate, salicylic acid, tocopheryl acetate, a mixture of water, alcohol and Perilla extract, sodium hyaluronate, panthenol, propylene glycol and apple ⁇ P rus Malus) , propylene glycol and pineapple, ivy ⁇ Hedera hal ix) extract and 1,3-B.G, peach ⁇ Prums persica ) leaf extract, hydrolyzed soy flour, wheat ⁇ Tri ticum Vulgare) protein, birch ⁇ Betula alba ) extract and 1,3-B.G, burdock (Arctium majus) extract and 1,3-B.G; liposomes; phosphatidylcholines; esters, such as glyceryl stearate, captylic/capric
  • fatty acid it is preferable to use oleic acid, cetyl alcohol, stearyl alcohol, stearic acid, myristic acid, linoleic acid or lauric acid. More preferable is to use oleic acid, linoleic acid, or isopropyl myristate.
  • water-soluble matrix polyethylene glycol (PEG), carbowax or polyvmyl pyrrolidone (PVP) is available.
  • PEG polyethylene glycol
  • PVP polyvmyl pyrrolidone
  • Aforementioned water-soluble matrix may be used in combination with other matrixces, examples of which include water-soluble matrices such as gelatin, gum, carbohydrates, celluloses, polyvmyl alcohol, polyacrylic acid, inorganic compounds and mixtures thereof; and enteric matrices such as hydroxypropylmethylcellulose acetyl succmate (HPMCAS) , cellulose acetate phthalate, shellac, zem, polyvmyl acetate phthalate, Eudragit L100, Eudragit S100, sodium argmate and poly-L-lysme .
  • HPMCAS hydroxypropylmethylcellulose acetyl succmate
  • a surfactant may be added, which is selected from the group comprising glyceryl stearate, polysorbate 60, polysorbate 80, sorbitan trioleate, sorbitan sesquioleate, sorbitan stearate, PEG-20 glyceryl isostearate , ceteth-25, PEG-60 hydrogenated castor oil, nonoxynol-15, PEG-6- decyltetradeceth-20, dimethicone copolyol, glyceryl diisostearate, ceteth-24, cetearyl alcohol, polyoxylethylene nonyphenyl ether, PEG-40 hydrogenated castor oil, cetyl dimethicone copolyol, polyglyceryl-3- methylglucose distearate, PEG-100 stearate, sorbitan isostearate, sodium lauryl glutamate, dis
  • the solid dispersed preparation of the present invention can be applied for all the poorly water-soluble drugs and preferably for ketoconazole; itraconazole and its derivatives; cyclosporine; cisapride; acetaminophen; aspirin; acetylsalicylic acid; indomethacin; naproxen; warfarin; papaverine; thiabendazole; miconazole; cinnarizine; doxorubicin; omeprazole; cholecalciferol ; melphalan; nifedipine; digoxin; benzoic acid; tryptophan; tyrosine; phenylalanine; aztreonam; ibuprofen; phenoxymethylpenicillin; thalidomide; methyltestosterone; prochlorperazine; hydrocortisone; dideoxypurine nucleoside; vitamin D-; sulfonamide; sulfonylurea;
  • the present invention has an advantage, in that, the solid dispersed preparation can be prepared with ease and show high efficiency in absorption and release.
  • a poorly water-soluble medicine is homogeneously mixed and dispersed in an oil, fatty acid or their mixture and added in water-soluble polymer matrices molten at room temperature or about 60-80 °C, after which the resulting mixture is cooled rapidly to room temperature and dried an oven for 12 hours or more.
  • the dried pellet is powdered in a mortar and passed through a sieve to give powder which is uniform in particle size.
  • the oil, fatty acid or their mixture may be emulsified or micro-emulsifled.
  • a surfactant may be added to the solution.
  • the solubility of the solid dispersed preparation is found to be better than those of poorly water-soluble drugs themselves.
  • a great advance can be brought into the solubility of poorly water-soluble drugs when they are incorporated into a solid dispersed preparation containing oleic acid or micro- emulsified oleic acid.
  • the superiority of the solid dispersed preparation according to the present invention is also demonstrated. Even when only a water-soluble matrix is used, the uptake efficiency of the drugs is minutely increased. In particular, the uptake efficiency of drugs in the gastro-intestinal tract is remarkably improved when they are incorporated in a solid dispersed preparation using oleic acid-containing microemulsions .
  • compositions of emulsions and microemulsions used in Examples.
  • the dried solid dispersed preparation was finely milled in a grinder and passed through a sieve to give a powder which was uniform in particle size.
  • a mixture of 10 g of aceclofenac, 2.5 g of oleic acid, 2.5 g of Tween 80, 5 g of talc and 10 g of PEG 6000 was heated at about 80 °C and homogeneously dispersed in 150 ml of an alcohol. With the aid of a fluid bed-coating machine (nozzle; 0.8 mm), the resulting solution was sprayed at a rate of 4 ml/min onto 35 g of sugar spheres to give a solid dispersed granule.
  • a mixture of 2.5 g of cisapride, 2.5 g of oleic acid, 2.5 g of Tween 80, 5 g of talc and 23 g of PEG 6000 was heated at about 80 °C and added with 150ml of a mixture of acetone and water (acetone : water, 1:1) . With the aid of a fluid bed-coating machine (nozzle; 0.8mm), the resulting mixture was sprayed at a rate of 4 ml/mm onto 100 g of sugar spheres.
  • Aceclofenac, lactose, starch and talc were mixed to give a tablet in accordance with the established method.
  • 2.5g of aceclofenac, 2.5g of oleic acid, 2.5g of tween 80, 3g of talc, 25g of Eudragit RS30D and 25g of Eudragit L30D were homogeniously mixed.
  • nozzle 0.8mm
  • the resulting mixture was sprayed at a rate of 4ml/min onto the said tablets to obtain a solid dispersed tablet.
  • Cisapride, lactose, starch and talc were mixed to give a tablet in accordance with the established method.
  • Eudragit RS30D and 25g of Eudragit L30D were homogeniously mixed. With the aid of a fluid bed-coating machine
  • the solubility of the drugs in distilled water was significantly improved when they were incorporated in solid dispersed preparations containing oleic acid.
  • the drugs in the solid dispersed preparations prepared from microemulsions containing oleic acid showed a great advance in the solubility m water as well as in artificial intestinal juice .
  • EXPERIMENT II The drug-releasing Rate of Solid Dispersed Preparations in Artificial Gastric and Intestinal Juices
  • the solid dispersed preparations comprising ketoconazole or cisapride, respectively, obtained m Examples, were tested for releasing rates in artificial gastric juice and artificial intestinal juice.
  • ketoconazole although it can be released in the artificial gastric juice to an extent because of its acidic property, is relatively further improved in the releasing level and percentage when it is incorporated in the oleic acid-containing solid dispersed preparations. Therefore, these data are consistent with those of Experiment I. In the meanwhile, cisapride was released to an extent by virtue of its solubility, but also considerably increased in the releasing properties when it was used in the solid dispersed preparations of the present invention .
  • microemulsified oleic acid brought about a great advance m the releasing properties.
  • a rabbit was killed by introducing air in its ear vein and its stomach, duodenum, jejunum, lleum, colon and rectum were excised and washed with physiological saline solution at 37 °C .
  • physiological saline solution warmed to 37 °C was poured, and stirred with a magnetic stirrer while the solid dispersed preparations obtained in Examples were added in the donor.
  • Samples were harvested from the receptor at predetermined times for 6 hours while the receptor was supplemented with a fresh physiological saline solution in order to constantly maintain the total volume in the receptor . The samples taken were measured for their plasma concentrations of drugs.
  • mice Male mice (Sprague-Dawley lineage) weighing 250-310 g, purchased from the Korea National Institute of Health, were adapted to new circumstances for 1-2 weeks. After the mice, which were starved from one day before the experiment, were etherized, their left femoral arteries were inserted with cannulas connected to syringes containing 80 IU/ml of hepa ⁇ n. After 2 hours, the mice came out of the ether and were administered with a suspension of the cyclospo ⁇ ne- containing solid dispersed preparation of the present invention and a commercially available preparation with the aid of a sonde. At an interval of a predetermined period of time, blood was taken from the left femoral arteries and measured for the plasma concentration of drug.
  • the cyclosporine level in blood are plotted against the times after administration for the solid dispersed preparations of the present invention and a commercially available preparation.
  • the plasma concentration of the solid dispersed preparations according to the present invention are similar to that of the commercially available preparation, Neoral .
  • the solid dispersed preparations according to the present invention are thought to have the initiatives to substitute for the conventional preparations which contain liquid drugs, in a pharmaceutical aspect.
  • aceclofenac although it can be released in the artificial gastric juice to an extent because of its basic property, is relatively further improved in the releasing level and percentage when it is formulated into the solid dispersed preparation.
  • EXPERIMENT VII Comparison of Plasma Concentration of Aceclofenac Between Solid Dispersed Preparation and Conventional Ones
  • mice Male mice ( Sprague-Dawley lineage) weighing 250-310 g, purchased from the Korea National Institute of Health, were adapted to new circumstances for 1-2 weeks. After the mice, which were starved from one day before the experiment, were etherized, their left femoral arteries were inserted with cannulas connected to syringes containing 50 IU/ml of heparin.
  • mice came out of the ether and were administered with a suspension of the aceclofenac- containing solid dispersed preparation of the present invention and a aceclofenac powder with the aid of a sonde.
  • blood was taken from the left femoral arteries and measured for the plasma concentration of the drug.
  • the aceclofenac-carrying solid dispersed preparations of the present invention and a commercial available preparation were orally administered to beagle dogs and volunteers.
  • blood was taken from the beagle dogs and the volunteers and measured for the drug levels.
  • the solid dispersed preparations of the present invention maintain higher levels of aceclofenac in blood for all of the testees than the commercially available preparation.
  • the use of the solid dispersed preparation according to the present invention was affirmed to increase the maximal value of plasma concentration and area under the curve, which are pharmacokmetic parameters, by 1.5-6 times.
  • the amount of the drug released from the solid dispersed preparation was increased almost linearly in both artificial gastric and intestinal juices, showing a zero order-like kinetics.
  • Cisapride Plasma Concentration of Cisapride ( ⁇ g/ml ] in Beagle Dog
  • the plasma concentration of cisapride is maintained at higher levels when the solid dispersed preparation of the present invention is used than when the conventional preparation.
  • the solid dispersed preparations of the present invention are improved in the solubility of poorly water-soluble drugs in the gastrointestinal tract, in detail, the releasing of the drugs against the gastric and intestinal juices, resulting in a great increase in the bioavailability of the drugs.
  • the solid dispersed preparations of the present invention give the pharmaceutical solutions to the problems that the conventional semi-solid or liquid preparations possess, enabling medicinally effective, poorly water- soluble compounds to be formulated, molded and processed, quickly and in an economically favorable manner without use of any organic solvent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is a solid dispersed preparation for poorly water-soluble drugs, which is prepared by dissolving or dispersing the poorly water-soluble drugs in an oil, a fatty acid or a mixture thereof, mixing the solution or dispersion in a water-soluble polyol matrix and drying the mixture. The solid dispersed preparation can be formulated into a power formulation or a granule formulation. The solid dispersed preparation is improved in the solubility of poorly water-soluble drugs in the gastro-intestinal tract, resulting in a great increase in the bioavailability of the drugs. In addition, the solid dispersed preparation gives the pharmaceutical solutions to the problems that the conventional semi-solid or liquid preparations possess, enabling medicinally effective, poorly water-soluble compounds to be formulated, molded and processed, quickly and in an economically favorable manner without use of any organic solvent.

Description

SOLID DISPERSED PREPARATION OF POORLY WATER-SOLUBLE DRUG CONTAINING OIL, FATTY ACID OR MIXTURES THEREOF
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to a solid dispersed preparation for poorly water-soluble drugs or biologically active substances. More particularly, this invention relates to a solid dispersed preparation which allows poorly water-soluble drugs to be increased in the uptake efficiency in the gastro-intestinal track and is convenient to make in a pharmaceutical formulation.
Description of the Prior Art
A good many drugs poorly dissolve in water . When being administered to a body, these poorly water-soluble drugs have so low solubility and releasing rate in digestive juices as to retard their absorption, resulting the bioavailability decreased. In order to solve this problem, various preparation methods were developed with the aim of solubilizing these poorly water-soluble drugs and increasing their releasing rates. For instance, there have been reported many methods for improving the bioavailability of drugs, including micronization, formation of micelles by use of surfactant, solvent deposition, utilization of dry elixirs, co-precipitation by use of inert water-soluble carriers, solid-dispersion and formation of inclusion complexes using cyclodextrins .
In conducting these methods, however, the drugs to be administered do not show a constant increase in solubility. Thus, they are problematic in terms of preparation, commercialization, and efficiency.
For the poorly water-soluble drugs, which are also poor in internal uptake, there have been made attempts to enhance their bioavailability upon administration. However, the dosage forms developed thus far, are of semi-solid or liquid form, giving disadvantages in pharmaceutics, especially in formulating, molding and processing .
SUMMARY OF THE INVENTION
We, the inventors made the intensive and thorough research on the formulation of poorly water-soluble drugs, to improve the bioavailability of the drugs upon administration. As a result, we found that the dispersion or solution of the poorly water-soluble drugs in oils, fatty acids or mixtures thereof, followed by mixing with a water-soluble polymer matrix allowed the drugs to efficiently release in the gastro-intestinal tract and the mixture can be formed into a solid form.
Therefore, it is an object of the present invention to provide a solid dispersed preparation which improves the bioavailability of poorly water-soluble drugs by enhancing the release of the drugs in the gastro-intestinal tract. It is another object of the present invention to provide a solid dispersed preparation which can be prepared by simple and convenient process with an economical benefit .
According to the present invention, a solid dispersed preparation for poorly water-soluble drugs is prepared by dissolving or dispersing the drugs in an oil, a fatty acid or a mixture thereof, mixing the solution or dispersion in a water-soluble polyol matrix and drying the mixture.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a graph in which the plasma concentration of cyclosporine is plotted against the times after administrating the solid dispersed preparations of the present invention (closed rectangle and closed triangle) and a commercially available preparation (Neoral, closed lozenge) ;
Fig. 2 is a graph in which the plasma concentration of aceclofenac is plotted against the times after orally administrating aceclofenac powder (closed circle) and the solid dispersed preparation of the present invention (open circle, oleic acid 5%) to rats;
Fig. 3 is a graph in which the plasma concentration of cyclosporine is plotted against the times after administrating the solid dispersed preparation of the present invention (closed circle, capsule containing 100 mg of the preparation) and a commercially available preparation (open circle, Airtal capsule 100 mg ) to bealgle dogs;
Fig. 4 is a graph in which the plasma concentration of aceclofenac is plotted against the times after orally administrating the solid dispersed preparation of the present invention (closed circle, capsule containing 100 mg of the preparation) and a commercially available preparation (open circle, Airtal capsule 100 mg) to humans; and
Fig. 5 is a graph in which the plasma concentration of cisapride is plotted against the times after orally administrating the solid granular preparations of the present invention (open circle, bead 10 mg) and a commercially available preparation (closed circle, prepulsid 10 mg) to humans.
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail.
In accordance with the present invention, there is provided a solid dispersed preparation for poorly water- soluble drugs, which is prepared by dispersing or dissolving the drugs in an oil, a fatty acid or a mixture thereof, incorporating the dispersion or solution into a water-soluble polymer matrix and drying this mixture.
In particular, this invention provides two types of fomulation, i.e., the solid powdery preparation and the solid granular preparation.
The preparation method of the solid dispersed powders comprises the following steps; Dissolving or dispersing the poorly water-soluble drugs in an oil, a fatty acid or the mixture thereof; mixing with the water-soluble polymer matrix; drying the mixture; and grinding the pellet into powders .
In addition, the preparation method of the solid dispersed granules comprises the following steps; Dissolving or dispersing the poorly water-soluble drugs in an oil, a fatty acid or the mixture thereof; mixing with the water-soluble polymer matrix; spraying onto a pharmaceutically acceptable nucleus, resulting the granules. In a preferred embodiment , the pharmaceutically acceptable nucleus may be a sugar sphere. The solid dispersed powdery preparation or the solid dispersed granular preparation of this invention can be formulated into the pharmaceutically acceptable medicines for internal use such as powders, granules, tablets and capsules . Hereinafter, the word "solid dispersed preparation" means "solid dispersed powdery preparation", "solid dispersed granular preparation" or the both. In this regard, the oil, the fatty acid or the mixture thereof may be used alone or in a form of an emulsion or microemuls on inclusive of itself. When dispersing or dissolving poorly water-soluble drugs in the oil, fatty acid or mixture thereof , a surfactant may be added together . Further, the water-soluble polymer matrix may be used alone or in combination with another water-soluble matrix.
Illustrative examples of the oil that can be used in the preparation of the present invention include lipid additives, such as α-bisabolol, stearyl glycerrhetmate, salicylic acid, tocopheryl acetate, a mixture of water, alcohol and Perilla extract, sodium hyaluronate, panthenol, propylene glycol and apple { P rus Malus) , propylene glycol and pineapple, ivy { Hedera hal ix) extract and 1,3-B.G, peach { Prums persica ) leaf extract, hydrolyzed soy flour, wheat { Tri ticum Vulgare) protein, birch { Betula alba ) extract and 1,3-B.G, burdock (Arctium majus) extract and 1,3-B.G; liposomes; phosphatidylcholines; esters, such as glyceryl stearate, captylic/capric triglyceride, cetyl octanolate, isopropyl myristate, 2-ethylene isopelagonate, dι-C12-13 alkyl malate, ceteatyl octanoate, butylene glycol dicaptylate/dicaprate, isononyl isostearate, isostearyl isostearate, coco-captylate/caprate, cetyl octanoate, octyldodecyl myristate, cetyl esters, C10-30 cholesterol/lanosterol ester, hydrogenated castor oil, monoglycendes , diglycerides, and tπglycerides ; hydrocarbons, such as beeswax, canauba wax, suctose distearate, PEG-8 beeswax and candelilla { euphorbia ce ifera ) wax; mineral oils such as ceresin and ozokerite; vegetable oils such as macadamia ternifolia nut oil, hydrogenated hi-erucic acid rape seed oil, olive oil, jojoba oil, hybridsunflower { Hel ian th us annuus ) oil, neen {mel ia a zadira ch ta ) seed oil, dog rose { rosa canina ) lips oil with preference to mineral oils, squalene, squalane, monoglycerides , diglycerides, triglycerides , medium-chain glyceride, myglyol, cremophor, hydrogenated caster oil, corn oil, Perilla oil, cotton seed oil and lipid-soluble vitamins .
As for the fatty acid, it is preferable to use oleic acid, cetyl alcohol, stearyl alcohol, stearic acid, myristic acid, linoleic acid or lauric acid. More preferable is to use oleic acid, linoleic acid, or isopropyl myristate.
As the water-soluble matrix, polyethylene glycol (PEG), carbowax or polyvmyl pyrrolidone (PVP) is available. Aforementioned water-soluble matrix may be used in combination with other matrixces, examples of which include water-soluble matrices such as gelatin, gum, carbohydrates, celluloses, polyvmyl alcohol, polyacrylic acid, inorganic compounds and mixtures thereof; and enteric matrices such as hydroxypropylmethylcellulose acetyl succmate (HPMCAS) , cellulose acetate phthalate, shellac, zem, polyvmyl acetate phthalate, Eudragit L100, Eudragit S100, sodium argmate and poly-L-lysme . In order to enhance the dispersion or dissolution of poorly water-soluble drugs in the oil, fatty acid or their mixture, a surfactant may be added, which is selected from the group comprising glyceryl stearate, polysorbate 60, polysorbate 80, sorbitan trioleate, sorbitan sesquioleate, sorbitan stearate, PEG-20 glyceryl isostearate , ceteth-25, PEG-60 hydrogenated castor oil, nonoxynol-15, PEG-6- decyltetradeceth-20, dimethicone copolyol, glyceryl diisostearate, ceteth-24, cetearyl alcohol, polyoxylethylene nonyphenyl ether, PEG-40 hydrogenated castor oil, cetyl dimethicone copolyol, polyglyceryl-3- methylglucose distearate, PEG-100 stearate, sorbitan isostearate, sodium lauryl glutamate, disodium cocoamphodiacetate, lauric acid diethanolamide, coconut fatty acid diethanolamide, N, N-bis- (2-hydroxy ethyl) - cocomide, and cocoamidopropyl betain.
The solid dispersed preparation of the present invention can be applied for all the poorly water-soluble drugs and preferably for ketoconazole; itraconazole and its derivatives; cyclosporine; cisapride; acetaminophen; aspirin; acetylsalicylic acid; indomethacin; naproxen; warfarin; papaverine; thiabendazole; miconazole; cinnarizine; doxorubicin; omeprazole; cholecalciferol ; melphalan; nifedipine; digoxin; benzoic acid; tryptophan; tyrosine; phenylalanine; aztreonam; ibuprofen; phenoxymethylpenicillin; thalidomide; methyltestosterone; prochlorperazine; hydrocortisone; dideoxypurine nucleoside; vitamin D-; sulfonamide; sulfonylurea; p- aminobenzoic acid; melatonin; benzylpenicillin; chlorambucil; diazepin; digitoxin; hydrocortisone butyrate; metronidazole benzoate; tolbutamide; prostaglandin ElfPGE ; fludrocortisone; griseofulvin; miconazole nitrate; leukotriene B„ antagonist; propranolol; thephylline; flubiprofen; sodium benzoate; benzoic acid; riboflavin; benzodiazepine; phenobardital; glyburide; sulfadiazine; sulfaethylthiadiazole; sodium diclofenac; aceclofenac; phyniroin; hioridazinehydrochloride; bropirimine; hydrochlorothiazide; fluconazole; acyclovir; bucillamine; ciprofluoxacin; acetyl-L-carnitine; baclofen; sodium alendronate; lovocarnitine; nimodipine or nimodifine; atenolol; provastatin sodium; lovastatin; isotretinoin; etidronate disodium; doxifluridine; fosfomycin calcium; sotepine; epinastine hydrochloride; carvedilol; epinastine hydrochloride; carvedilol; fosinopril; trandolapril; etretinate cap; metergoline; mercaptopurine; vancomycin hydrochloride; cefixime; cefuroxim axetil; dirithramycin; and dadanosin and more preferably for ketoconazole, itraconazole and its derivatives, cisapride, cyclosporine and nifedipine.
Over conventional methods, the present invention has an advantage, in that, the solid dispersed preparation can be prepared with ease and show high efficiency in absorption and release. First, a poorly water-soluble medicine is homogeneously mixed and dispersed in an oil, fatty acid or their mixture and added in water-soluble polymer matrices molten at room temperature or about 60-80 °C, after which the resulting mixture is cooled rapidly to room temperature and dried an oven for 12 hours or more. The dried pellet is powdered in a mortar and passed through a sieve to give powder which is uniform in particle size. As aforementioned, when the drug is dispersed or dissolved in the oil, fatty acid or their mixture, the oil, fatty acid or their mixture may be emulsified or micro-emulsifled. In this case, a surfactant may be added to the solution.
Alternatively, after the homogeneous dispersion of the poorly water-soluble drug is added in the water-soluble polymer matrix molten at about 60-80 °C, it may be sprayed to pharmaceutically acceptable nucleus to give a granule. As a consequence of an examination which was made on the solubility of the solid dispersed preparation in distilled water, artificial intestinal juice and artificial gastric juice, the solubility of the solid dispersed preparation is found to be better than those of poorly water-soluble drugs themselves. Particularly, a great advance can be brought into the solubility of poorly water-soluble drugs when they are incorporated into a solid dispersed preparation containing oleic acid or micro- emulsified oleic acid.
The data obtained from the experiments in which the solid dispersed preparations of the present invention are eluted in artificial gastric juice and artificial intestinal juice, show that the solid dispersed preparations of the present invention are superior to the poorly water-soluble drugs themselves in releasing rate. A significant improvement in releasing rate is observed when a solid dispersed preparation containing oleic acid or microemulsified oleic acid is used. In the artificial intestinal juice, a severer condition in which for drugs to dissolve, rather than in the artificial gastric juice, the improvement in the releasing rate by virtue of the solid dispersed preparation is more apparent.
Through an experiment which is conducted for examining the uptake efficiency of poorly water-soluble drugs in the gastro-intestinal tract, the superiority of the solid dispersed preparation according to the present invention is also demonstrated. Even when only a water-soluble matrix is used, the uptake efficiency of the drugs is minutely increased. In particular, the uptake efficiency of drugs in the gastro-intestinal tract is remarkably improved when they are incorporated in a solid dispersed preparation using oleic acid-containing microemulsions .
In addition, comparison of the plasma concentration of target drug molecule after oral administration between the solid dispersed preparation and conventional preparations, is helpful in understanding the present invention. As a result, similar levels are observed, suggesting that the solid dispersed preparation of the present invention can substitute for conventional preparations when account is taken of pharmaceutical aspects.
A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.
Following are the compositions of emulsions and microemulsions used in Examples.
EMULSIONS
PREPARATION EXAMPLE I
Waxes Composition (!
KALCHOL 6870 1.800
EMERSOL 132 1.000
Multi-Wax W-445 1.700
Emulsifiers
ATLAS G-144 1.800
ATLAS G-610 1.900
ATMOS 370 0.800
KM-105 2.000
Oils
CRODALAN SWL 1.500 LEXOL GT 865 4.000
NIKKOL CIO 4.000
SEPERIOR JOJOBA OIL 1.000
SF 1202 0.200
KF-96(100CS) 0.300
DRAKEOL 7 5.000
Squalane 2.000 dl-a-Tocopheryl Acetate 0.100
POLYOLPERPOLYMER-2 0.200
Aqueous Phase DI-WATER 60.852 glycerin 2.000 P.G 7.000
NATURAL EXT.AP 0.500 LUBRAGEL CG 0.200 Carbopo 1940 0.100 KELTROL F 0.020 NaOH 0.028
PREPARATION EXAMPLE II
Waxes
KALCHOL 6870 1.800 EMERSOL 132 1.000 Multi-wax W-445 1.700 Emul si f iers
RHEODOL AO-15 0.800
RHEODOL MS-162 2.000
RHEODOL TW-S120 1.900 KM-105 2.000
Oils
CRODALAN SWL 1.500
LEXOL GT 865 5.000 NIKKOL CIO 2.500 Macadamia ternifolia nut oil 1.000
SF 1202 0.300
KF-96(100CS) 0.300
DRAKEOL 7 7.000 Squalane 0.500 dl-a-Tocopheryl Acetate 0.100
POLYOLPERPOLYMER-2 0.100
Aqueous phase DI-WATER 61.780 glycerin 2.000
1.3-B.G 6.000
NATURAL EXT.AP 0.300
LUBRAGEL CG 0.200 Carbopol 940 0.100
KELTROL F 0.020
TEA 0.100 PREPARATION EXAMPLE III
Waxes
KALCHOL 6870 0.500 EMERSOL 132 0.500
Beeswax 0.400
Emulsifiers
ATLAS G-114 2.200 ATLAS G-610 0.800
ATMOS 370 0.800
KM-105 0.700
Oils CRODALAN SWL 0.500
LEXOL GT 865 3.000
NIKKOL CIO 3.000
SUPERIOR JOJOGA OIL 0.500
SR 1202 0.200 KF-96(100CS) 0.100
DRAKEOL 7 3.000
Squalane 0.500 dl-a-Tocopheryl Acetate 0.100
POLYOLPERPOLYMER-2 0.200
Aqueous phase
DI-WATER 74.146 Glycerin 2.000
P.G 6.000
NATURAL EXT.AP 0.500
LUBRAGEL CG 0.200
Carbopol 940 0.100
KELTROL F 0.020
NaOH 0.0336
PREPARATION EXAMPLE IV
Waxes
KALCHOL 6870 0.400 EMERSOL 132 0.500 Multi-Wax W-445 0.400
Emulsifiers
RHEODOL AO-15 0.800 RHEODOL MS-165 2.200 RHEODOL TW-S120 0.800 KM-105 0.600
Oils
CRODALAN SWL 0.500
LEXOL GT 865 3.000
NIKKOL CIO 2.000
Macadamia ternifolia nut oil 1.000 SF 1202 0.400 DRAKEOL 7 4.500 Squalane 0.500 dl-a-tocopheryl acetate 0.100 POLYOLPERPOLYMER-2 0.100
Aqueous phase DI-WATER 73.480 glycerin 2.000 1, 3-B.G 6.000
NATURAL EXT.AP 0.300 LUBRAGEL CG 0.200 Cabopol 0.100 KELTROL F 0.020 TEA 0.100
MICROEMULSIONS
PREPARATION EXAMPLE V
Waxes
Cetyl Alcohol 3.000
Emulsifiers
NIKKOL HCO-60 5.000 RHEODOL TW-0120 5.000 Cremophor EL 20.000 Oils
I .P.M 5.000 CAPTEX 5.000
Aqueous phase DI-WATER 52 . 000 Ethanol 5 . 000
PREPARATION EXAMPLE VI
Emulsifiers
NIKKOL HCO-60 5.000 RHEODOL TW-0120 5.000 Cremophor EL 5.000
Oils
I. P.M 5.000
Lanolin oil 5.000 CAPTEX 5.000
Aqueous phase DI-WATER 50.000
PREPARATION EXAMPLE VII
Surfactant
LABRASOL 15.000 Surfactant Aid
Polyglyceryl oleate 5.000 PLURL OLEIQUE 5.000
Oil phase
LABRAFIL M1994CS 4.500
Sub-Solvent Transcutol 5.000
Aqueous phase
Phosphate buffer (pH 6] 64.500
PREPARATION EXAMPLE VIII
Oil phase
GELUCIRE 44/14 11.429 GELUCIRE 48/09 11.429
Surfactant
LABRAFAC CM 10 10.714
Surfactant Aid
LAUROGLYCOL 7.143 Transcutol 59.285
PREPARATION EXAMPLE IX Aqueous Phase
Water (Buffer) 57,050
Physiological Saline Solution 4,000 Glucose 1,000
Propylene Glycol PEG 300,400 5,000
Glycerol 5,000
Oil Phase Fatty Acid Esters 5,000
Modified Vegetable Oil 0.500
Silicon Oil 0.500
Surfactant Aid Long Chain Alcohol 3,750
Glycol Derivative 2,500
Propylene Glycol Derivative 1,200
Polyglycerol Derivative 4,500
Surfactant
Non-ionic Surfactant 10,000
PREPARATION EXAMPLE X
Oil Phase
Oleic Acid 6, 250 Surfactant
Tween 80 12,500
Surfactant Aid Transcutol 8,750
Aqueous Phase
Water 72,500
PREPARATION EXAMPLE XI
Oil Phase
Captex 5,000
Surfactant
Cremophor 12,500
Surfactant Aid
Transcutol 6,250
Aqueous Phase
Water 76,250
COMPARATIVE EXAMPLE I
After being melted at about 70 °C, 90 g of PEG 6000 was added with 10 g of ketoconazole, cooled rapidly to room temperature and dried in an oven for 12 hours or more. The dried solid dispersed preparation was milled in a mortar and passed through a sieve to give a powder which was uniform in particle size.
EXAMPLE I
In 5 g of oleic acid were homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added into 85 g of PEG 6000 which was molten at about 70 °C. After being cooled rapidly to room temperature and dried in an oven for 12 hours or more, the dried solid dispersed preparation was milled in a mortar and passed through a sieve to give a powder which was uniform in particular size.
EXAMPLE II
In 5 g of oleic acid and 5 g of Tween 80 were homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE III
In 5 g of isopropyl myristate was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE IV
In 5 g of liquid paraffin was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I .
EXAMPLE V
In 5 g of cremophor was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE VI
In 5 g of cremophor and 5 g of Tween 80 was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE VII
In 5 g of isopropyl myristate and 5 g of Tween 80 was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE VIII
In 5 g of liquid paraffin and 5 g of Tween 80 was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE IX
In a microemulsion containing 5 g of cremophor, 5 g of oleic acid, 35 g of alcohol and 1 g of transcutol was homogeneously dissolved and dispersed 10 g of ketoconazole, followed by evaporating the alcohol . The solid residue was, then, added in 43 g of PEG 6000 molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE X
In a microemulsion containing 5 g of cremophor, 5 g of oleic acid and 1 g of transcutol was dissolved 10 g of ketoconazole which was, then, dispersed in 35 g of distilled water, followed by evaporating the distilled water in an oven. The solid residue was added in 43 g of PEG 6000 molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE XI
In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of ketoconazole. 40 g of hydroxypropylmethylcellulose, an enteric matrix, was added in 40 g of PEG 6000 molten at 70 °C . Using the mixture of the above two solutions, a dispersed powdery preparation was obtained in the same procedure as in Example I .
EXAMPLE XII
In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of itraconazole which was, then, added in 80 g of PEG 6000 which was molten at 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I .
EXAMPLE XIII
In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of itraconazole. 40 g of hydroxypropylmethylcellulose, an enteric matrix, was added in 40 g of PEG 6000 which was molten at 70 °C . Using the mixture of the above two solutions, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE XIV
In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of an itraconazole derivative (Dong-A Pharmacy Co., Ltd., Korea) which was, then, added in 80 g of PEG 6000 which was molten at 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I .
EXAMPLE XV
In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of cyclosporine which was, then, added in 80 g of PEG 6000 which was molten at 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as Example I .
EXAMPLE XVI
In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of cyclosporine. 40 g of hydroxypropylmethylcellulose, an enteric matrix, was added in 40 g of PEG 6000 which was molten at 70 °C . Using the mixture of the above two solutions, a dispersed powdery preparation was obtained in the same procedure as m Example I.
EXAMPLE XVII
In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of cisapride which was, then, added in 80 g of PEG 6000 which was molten at 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE XVIII
In 5 g of oleic acid and 5 g of Tween 80 was homogeneously mixed and dispersed 10 g of cisapride -hich was, then, added in 80 g of PEG 6000 which was molten at 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE XIX
In a microemulsion containing 10 g of cremophor, 5 g of oleic acid and 7 g of transcutol was homogeneously dissolved and dispersed 10 g of itraconazole, followed by evaporating the alcohol in an oven. The solid residue was, then, added in 43 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE XX
In a microemulsion containing 10 g of cremophor, 4 g of captex and 5 g of transcutol was homogeneously dissolved and dispersed 10 g of cyclosporine, followed by evaporating the alcohol in an oven. The solid residue was, then, added in 43 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE XXI
In a microemulsion containing 10 g of cremophor, 5 g of oleic acid and 7 g of transcutol was homogeneously dissolved and dispersed 10 g of cisapride, followed by evaporating the alcohol in an oven. The solid residue was, then, added in 43 g of PEG 6000 which was molten at about 70 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE XXII
In 5 g of oleic acid was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of molten PVP. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I.
EXAMPLE XXIII
In a microemulsion containing 5 g of oleic acid was homogeneously mixed and dispersed 10 g of ketoconazole which was, then, added in 80 g of molten PVP. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example I .
COMPARATIVE EXAMPLE II
After being melted at about 70 °C, 2.5 g of molten PEG 6000 was added with 1.75 g of aceclofenac, cooled rapidly to room temperature and dried in a freeze-drier for 24 hours or more. The dried solid dispersed preparation was finely milled in a grinder and passed through a sieve to give a powder which was uniform in particle size.
EXAMPLE XXIV
In 0.25 g of oleic acid and 0.50 g of Tween 80 was homogeneously mixed and dispersed 1.75 g of aceclofenac, and then, the solution was added in 2.5 g of PEG 6000 which was molten at about 75 °C . After being cooled rapidly to room temperature
And dried in a freeze-drier for 24 hours or more, the dried solid dispersed preparation was finely milled in a grinder and passed through a sieve to give a powder which was uniform in particle size.
EXAMPLE XXV
In 0.25 g of cemophor and 0.50 g of Tween 80 was homogeneously mixed and dispersed 1.75 g of aceclofenac which was, then, added in 2.5 g of PEG 6000 which was molten at about 75 °C . Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example XXIV.
EXAMPLE XXVI In 0.25 g of labrasol and 0.50 g of Tween 80 was homogeneously mixed and dispersed 1.75 g of aceclofenac which was, then, added in 2.5 g of PEG 6000 molten at about
75 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example XXIV.
EXAMPLE XXVII
In 0.25 g of transcutol and 0.50 g of Tween 80 was homogeneously mixed and dispersed 1.75 g of aceclofenac which was, then, added in 2.5 g of PEG 6000 molten at about
75 °C. Using this mixture, a dispersed powdery preparation was obtained in the same procedure as in Example XXIV.
EXAMPLE XXVIII
A mixture of 10 g of aceclofenac, 2.5 g of oleic acid, 2.5 g of Tween 80, 5 g of talc and 10 g of PEG 6000 was heated at about 80 °C and homogeneously dispersed in 150 ml of an alcohol. With the aid of a fluid bed-coating machine (nozzle; 0.8 mm), the resulting solution was sprayed at a rate of 4 ml/min onto 35 g of sugar spheres to give a solid dispersed granule.
EXAMPLE XXIX
10 g of aceclofenac, 2.5 g of oleic acid, 2.5 g of Tween 80, 3 g of talc, 25 g of Euαragit (Rhompharm, Germany) RS30D and 25 g of Eudragit L3CD were homogeneously mixed. With the aid of a fluid bed-coating machine (nozzle; 0.8 mm), the resulting solution was sprayed at a rate of 4 ml/min onto 35 g of the sugar spheres prepared m Example XXVIII.
EXAMPLE XXX
10 g of aceclofenac, 2.5 g of oleic acid, 2.5 g of Tween 80, 3 g of talc and 50 g of Eudragit RS30D were homogeneously mixed. With the aid of a fluid bed-coating machine (nozzle;
0.8 mm), the resulting mixture was sprayed at a rate of 4 ml/mm onto the sugar spheres prepared in Example XXVIII.
EXAMPLE XXXI
A mixture of 2.5 g of cisapride, 2.5 g of oleic acid, 2.5 g of Tween 80, 5 g of talc and 23 g of PEG 6000 was heated at about 80 °C and added with 150ml of a mixture of acetone and water (acetone : water, 1:1) . With the aid of a fluid bed-coating machine (nozzle; 0.8mm), the resulting mixture was sprayed at a rate of 4 ml/mm onto 100 g of sugar spheres.
EXAMPLE XXXII
2.5 g of cisapride, 2.5 g of oleic acid, 2.5 g of Tween SO, 3 g of talc, 25 g of Eudragit RS30D and 25 g of Eudragit L30D were homogeneously mixed m 150ml of acetone. With tne aid of a fluid bed-coating machine (nozzle; 0.8 mm), the resulting mixture was sprayed at a rate of 4 ml/mm onto 70 g of the sugar spheres prepared in Example XXXI.
EXAMPLE XXXIII
Aceclofenac, lactose, starch and talc were mixed to give a tablet in accordance with the established method. 2.5g of aceclofenac, 2.5g of oleic acid, 2.5g of tween 80, 3g of talc, 25g of Eudragit RS30D and 25g of Eudragit L30D were homogeniously mixed. With the aid of a fluid bed- coating machine (nozzle; 0.8mm) , the resulting mixture was sprayed at a rate of 4ml/min onto the said tablets to obtain a solid dispersed tablet.
EXAMPLE XXXIV
Cisapride, lactose, starch and talc were mixed to give a tablet in accordance with the established method. 2.5g of cisapride, 2.5g of oleic acid, 2.5g of tween 80, 25g of
Eudragit RS30D and 25g of Eudragit L30D were homogeniously mixed. With the aid of a fluid bed-coating machine
(nozzle; 0.8mm) , the resulting mixture was sprayed at a rate of 4ml/mιn onto the said tablets to obtain a solid dispersed tablet . EXPERIMENT I The Drug Solubility of Solid Dispersed Preparation In Water and Artificial Intestinal Juice
In this experiment, the solubility of poorly water- soluble drugs in water and artificial intestinal juice was investigated for the solid preparations obtained in Comparative Example and Examples. In this regard, suspensions of 2 g of the solid dispersion preparations of this invention in water or artificial intestinal juice were filtrated through a 0.2 μm filter paper (Millipore, Waters, Milford, MA, USA) and the filtrate was diluteα for the convenient quantification of the drugs. The solubility results are given in Table 1.
TABLE 1
Solubility of Ketoconazole in distilled water and artificial intestinal juice
Figure imgf000036_0001
Figure imgf000037_0001
As apparent from the data of Table 1, the solubility of the drugs in distilled water was significantly improved when they were incorporated in solid dispersed preparations containing oleic acid. Particularly, the drugs in the solid dispersed preparations prepared from microemulsions containing oleic acid showed a great advance in the solubility m water as well as in artificial intestinal juice .
EXPERIMENT II : The drug-releasing Rate of Solid Dispersed Preparations in Artificial Gastric and Intestinal Juices
The solid dispersed preparations comprising ketoconazole or cisapride, respectively, obtained m Examples, were tested for releasing rates in artificial gastric juice and artificial intestinal juice.
According to the paddle process described in Korean Pharmacopoeia VI (KP VI), this releasing test was carried out in artificial gastric juice and artificial intestinal juice at 37±0.5 °C while the paddle was rotated at 50 rpm. At an interval of a predetermined period of time, samples were taken from the artificial juices and filtered through 0.2 μm Millipore paper and the filtrates were measured for plasma concentration of drug. The releasing levels and percentages of the poorly water-soluble drugs against artificial gastric and intestinal juices are given in Tables 2 and 3.
TABLE 2 Releasing Level (μg/ml) and Percentage (%) of Poorly- water-soluble Drugs in Artificial Gastric Juice
Figure imgf000038_0001
Figure imgf000039_0001
As shown in Table 2, ketoconazole, although it can be released in the artificial gastric juice to an extent because of its acidic property, is relatively further improved in the releasing level and percentage when it is incorporated in the oleic acid-containing solid dispersed preparations. Therefore, these data are consistent with those of Experiment I. In the meanwhile, cisapride was released to an extent by virtue of its solubility, but also considerably increased in the releasing properties when it was used in the solid dispersed preparations of the present invention .
TABLE 3 Releasing Level (μg/ml) and Percentage (%) of Poorly water-soluble Drugs in Artificial Intestinal Juice
Figure imgf000039_0002
II (-.82' (7.94) (8.15) (8. '5) (8.13) ( 8. / 3 ) (8.98 > (9.04) (9.42)
Exmp . 1.44 1.45 1.46 1.6"> 1.77 1.92 1.95 2.14 2.36 Ill (3.00) (3.04) (3.05) (3.47) (3.69) (3.99) (4.06; (4.47) (4.92)
Exmp. 1.03 1.27 1.31 1.36 1.45 1.48 1.57 1.63 1.69
IV (2.23) (2.76) (2.84) (2.95) (3.15) (3.21) (3.41) (3.54) (3.67)
Exmp. 2.21 2.23 2.21 2.27 2.31 2.33 2.47 2.38 2.40 V (4.89! (4.94) 15.03) (5.10) (5.15) (5.46) (5.26) (5.34) (5.30)
Exmp. 2.78 2.53 2.42 2.54 2.19 2.41 2.3 2.34 2.45 VI (6.00) (5.47) (5.23) (5.49) (4.72) (5.21) (4.97) (5.06) (5.29)
Exmp. 2.09 2.03 2.1 2.20 2.07 2.2 2.16 2.08 2.08 VII (4.28) (4.16) (4.31) (4.51) (4.26) (4.52) (4.43) (4.26) (4.26)
Exmp. 2.26 2.51 2.42 2.64 2.58 2.57 2.42 2.52 2.59 VIII (5.07) (5.61) (5.42) (5.92) (5.77) (5.76) (5.41) (5.64) (5.81)
Exmp. 3.55 3.95 4.12 4.27 4.28 4.34 4.38 4.38 4.36 IX (10.70) (11.89 (12.41) (12.86) (12.88) (13.08) (13.19) (13.20) (13.13
)
Exmp. 2.37 2.48 2.39 2.14 2.78 2.67 3.42 3.61 3.63 X (6.75) (7.05) (6.79) (6.08) (7.92) (7.60) (9.72) (10.27) (10.33
Cisa- 0 - 0 0 0 0.005 0.028 0.0745 pride (0) (0) (0) (0) (0.047) (0.27) (0.618 Powder
Exmp. - 2.43 - 3.22 2.70 2.66 2.64 3.10 3.99 XVII (20.15 (26.7) (22.42) (22.1) (21.94) (25.73) (33.12 )
Exmp. - 6.34 - 6.75 6.56 6.55 6.69 6.74 6.96 XVIII (63.0) (67.01) (65.15) (65.05) (66.46) (66.9) (69.05
The effect of the solid dispersed preparations on improving the releasing rates of the two drugs is more apparent in the artificial intestinal juice, a more difficult condition in which for the two drugs to dissolve.
As shown in Table 3, the releasing properties of drugs are better when they are incorporated in the solid dispersed preparations using fatty acid and oil than when they are used alone. A better improvement effect was obtained from the solid dispersed preparations containing oleic acid.
Further, the use of microemulsified oleic acid brought about a great advance m the releasing properties.
In a ddition, the solid dispersed preparations containing itraconazole, its derivatives , and cyclosporine, respectively, was tested for the releasing properties in the artificial gastric and intestinal juices. The results are given in Table 4. Also, the data of Table 4 demonstrate that the drugs in the solid dispersed preparations are superior to the drugs alone in the releasing properties.
TABLE 4
Releasing Level (μg/ml) of Poorly water-soluble Drugs Artificial Gastric and Intestinal Juice
Figure imgf000041_0001
1 Itrakonazole powder - Itra konazole denvati /e Cyclosporine
EXPERIMENT III : Uptake of Poorly water-soluble Drugs in Rabbit 's Gastrointestinal tract
The solid dispersed preparations containing ketoconazole, prepared from Examples, were tested for the uptake in rabbit's gastrointestinal tract. The results are given in Table 5.
In this regard, first, a rabbit was killed by introducing air in its ear vein and its stomach, duodenum, jejunum, lleum, colon and rectum were excised and washed with physiological saline solution at 37 °C . These organs were fixed between the receptor and donor of a Franz diffusion cell. In the receptor, a physiological saline solution warmed to 37 °C was poured, and stirred with a magnetic stirrer while the solid dispersed preparations obtained in Examples were added in the donor. Samples were harvested from the receptor at predetermined times for 6 hours while the receptor was supplemented with a fresh physiological saline solution in order to constantly maintain the total volume in the receptor . The samples taken were measured for their plasma concentrations of drugs.
TABLE 5
Uptake (μg/cm ) of Ketoconazole in Rabbit's GI tract
Figure imgf000042_0001
Exmp . I 1.72 3.44 5.46 9.10 10.2 1^.6 13.2
Exmp. II 0.50 2.7! 5.50 9.83 15.5 16.3 18.6 22.4
It is apparent from the data of Table 5 that the uptake of the drug in the GI tract is much better when it is incorporated in the solid dispersed preparation using oleic acid than when it is incorporated in the conventional dispersed preparation which uses a water-soluble matrix merely. Particularly, a significant improvement m the uptake of ketoconazole in the GI tract was brought about by the use of the solid dispersed preparations obtained from microemulsions containing oleic acid. These results are consistent with those of Experiment I and II.
EXPERIMENT IV: Comparison of the Plasma Concentration of Drugs Formulated into a Solid Dispersed Preparation and Commercially Available Ones
Before an experiment, male mice (Sprague-Dawley lineage) weighing 250-310 g, purchased from the Korea National Institute of Health, were adapted to new circumstances for 1-2 weeks. After the mice, which were starved from one day before the experiment, were etherized, their left femoral arteries were inserted with cannulas connected to syringes containing 80 IU/ml of hepaπn. After 2 hours, the mice came out of the ether and were administered with a suspension of the cyclospoπne- containing solid dispersed preparation of the present invention and a commercially available preparation with the aid of a sonde. At an interval of a predetermined period of time, blood was taken from the left femoral arteries and measured for the plasma concentration of drug.
With reference to Fig. 1, the cyclosporine level in blood are plotted against the times after administration for the solid dispersed preparations of the present invention and a commercially available preparation. As shown in the graph, the plasma concentration of the solid dispersed preparations according to the present invention are similar to that of the commercially available preparation, Neoral . Although being a little bit lower concentration than that of Neoral as a whole, the solid dispersed preparations according to the present invention are thought to have the initiatives to substitute for the conventional preparations which contain liquid drugs, in a pharmaceutical aspect.
Solid dispersed preparations according to the present invention and a commercial available preparation, all containing itraconazole as a medicinally effective ingredient, were administered to beagle dogs in an oral route. After a blood sample was taken from their veins at an interval of a predetermined period of time, the plasma concentration of drug was measured. The results are given in Table 6. TABLE 6
Itraconazole Level (μg/ml) in Blood According to Times
Figure imgf000045_0001
As apparent from Table 6, a similar pharmacokmetic pattern was observed between the plasma concentration of itraconazole from the solid dispersed preparations and from the conventional preparation (itazol) when starved beagle dogs were administered therewith, while the lower value shown case the preparation of Examp . XII was administrated. In non-starved beagle dogs, the drug reached a high maximal level in blood within a fast period of time when the commercially available preparation was administered whereas the preparation of Example XIII maintained the plasma concentration of drug constantly, owing to its solubilization m the gastro-mtestmal tract.
EXPERIMENT V: Solubility of Aceclofenac in Various Vehicles
Excess aceclofenac was added in 5 ml of a vehicle in a test tube, which was then voltexed to an extent that the drug was not dissolved further, and incubated for 3 days in a 37 °C water bath. The resulting solution was filtrated through a 0.2 μm filter paper (Millipore, Waters, Milford, MA, USA) and the filtrate was diluted for the convenient quantification of the drug. The solubility results are given in Table 7.
Table 7
Solubility of Aceclofenac in Vehicles
Figure imgf000046_0001
As apparent from the data of Table 7, large values are found in the solubility of aceclofenac in fatty acids, triacetin, castor oil and cremophor. Particularly, the drug is dissolved at great amounts in transcutol, labrasol and Tweens .
EXPERIMENT VI : Releasing of Aceclofenac in Solid Dispersed Preparations Against Artificial Gastric and Intestinal Juices
The solid dispersed preparations comprising aceclofenac, ootained in Examples XXIV to XXVII, were tested for releasing properties against artificial gastric juice and artificial intestinal juice in a similar manner to that of Experimental Example II.
The releasing levels and percentages of the poorly water-soluble drugs against artificial gastric and intestinal juices are given in Tables 8 and 9.
Table 8
Releasing Level (μg/ml) and Percentage (%) of Aceclofenac in Artificial Gastric Juice
Figure imgf000047_0001
As shown in Table 8, the releasing of aceclofenac in the artificial gastric juice was much improved when it was in the solid dispersed preparations of the present invention relatively to the other preparations.
TABLE 9
Releasing Level (μg/ml) and Percentage (%) of Aceclofenac in Artificial Intestinal Juice
Prep. fTime (hours)
0.25 0.5 0.75 1.0 1.5 2.0 3.0 5.0
Aceclo. 88.37 117.34 121.65 126.64 128.10 131.70 136.55 136.55 Powder (44.19) (58.67) 60.82 (63.32) (64.05) (65.85) (68.27) (68.28)
Exmp. 152.97 157.43 161.90 160.40 162.66 164.09 165.27 166.71 XXIV (76.49) (78.72) 80.95 (80.20) (81.33) (82.05) (82.63) (83.35)
Exmp . 151.72 163.33 161.72 163.11 162.26 165.57 166.16 166.16 XXV (75.86) (81.67) 80.86 (81.55) (81.13) (82.79) (83.08) (83.08)
Exmp. 148.21 152.40 154.58 154.95 154.49 155.48 157.97 159.74 XXVI (74.10) (76.20) 77.29 (77.47) (77.24) (77.74) (78.99) (79.87)
Exmp. 138.83 150.41 155.85 161.51 161.63 163.29 164.22 167.36 XXVII (69.41) (75.21) 77.92 (80.75) (80.81) (81.64) (82.11) (83.68)
Airtal 133.76 136.54 136.62 137.70 142.55 145.72 143.66 142.34 (66.88) (68.27) 68.31 (68.85) (71.28) (72.86) (71.83) (71.17)
As known from Table 9, aceclofenac, although it can be released in the artificial gastric juice to an extent because of its basic property, is relatively further improved in the releasing level and percentage when it is formulated into the solid dispersed preparation.
EXPERIMENT VII : Comparison of Plasma Concentration of Aceclofenac Between Solid Dispersed Preparation and Conventional Ones Before an experiment, male mice ( Sprague-Dawley lineage) weighing 250-310 g, purchased from the Korea National Institute of Health, were adapted to new circumstances for 1-2 weeks. After the mice, which were starved from one day before the experiment, were etherized, their left femoral arteries were inserted with cannulas connected to syringes containing 50 IU/ml of heparin. After 2 hours, the mice came out of the ether and were administered with a suspension of the aceclofenac- containing solid dispersed preparation of the present invention and a aceclofenac powder with the aid of a sonde. At an interval of a predetermined period of time, blood was taken from the left femoral arteries and measured for the plasma concentration of the drug. In the meanwhile, the aceclofenac-carrying solid dispersed preparations of the present invention and a commercial available preparation were orally administered to beagle dogs and volunteers. At predetermined times after oral administration, blood was taken from the beagle dogs and the volunteers and measured for the drug levels. After the oral administration of the aceclofenac- carrying solid dispersed preparations of the present invention, an aceclofenac powder and a commercial available preparation to mice, beagles dogs and volunteers, the plasma concentration of the drug with time were compared and are plotted in Figs. 2 to 4. As shown in the graphs, the solid dispersed preparations of the present invention maintain higher levels of aceclofenac in blood for all of the testees than the commercially available preparation. In addition, the use of the solid dispersed preparation according to the present invention was affirmed to increase the maximal value of plasma concentration and area under the curve, which are pharmacokmetic parameters, by 1.5-6 times. After the oral administration of the aceclofenac-carrying solid dispersed preparation of the present invention, a commercially available preparation and an aceclotenac powder, the plasma concentration of aceclofenac was monitored with time and the results are given in Tables 10 to 12, below.
TABLE 10
Aceclofenac Level (μg/ml) in Blood of Rat
Figure imgf000050_0001
It is apparent from the data of Table 10 that the aceclofenac level in blood is significantly improved when the drug is administered by use of the preparation of the present invention relative to when aceclofenac is administered alone.
TABLE 11 Plasma Concentration (μg/ml) of Aceclofenac in Beagle Dogs
Figure imgf000051_0001
The data of Table 11 demonstrate that the aceclofenac-carrying solid dispersed preparation of the present invention is superior to the conventional preparation in the plasma concentration.
TABLE 12
Plasma Concentration (μg/ml) of Aceclofenac in Human Blood
Figure imgf000051_0002
As apparent from the data of Table 12, higher levels of aceclofenac in blood are maintained when the solid dispersed preparation of the present invention is administered than when the commercially available preparation is used.
EXPERIMENT VIII : Releasing of Cisapride From Solid Dispersed Preparations Against Artificial Gastric and Intestinal Juices
The solid dispersed preparation comprising cisapride, obtained in Examples XXXI, was tested for releasing properties against artificial gastric juice and artificial intestinal juice in a similar manner to that of Experimental Example II .
The releasing levels and percentages of the poorly water- soluble drugs against artificial gastric and intestinal juices are given in Table 13.
TABLE 13
Releasing Level (μg/ml) and Percentage (%) of Cisapride in Artificial Gastric and Intestinal Juice
Figure imgf000052_0001
The amount of the drug released from the solid dispersed preparation was increased almost linearly in both artificial gastric and intestinal juices, showing a zero order-like kinetics.
EXPERIMENT IX: Comparison of Plasma Concentration of Cisapride Between Solid Dispersed Preparation and Commercially Available Ones
At an interval of a predetermined period of time after the oral administration of beagle dogs with the cisapride-carrying solid dispersed preparation obtained in Example XXXII and a commercially available preparation, blood was taken from the testees and measured for plasma concentration of drug. With reference to Fig. 5, the cisapride levels in blood are plotted against the times after administration for the solid dispersed preparations of the present invention and a commercially available preparation, Prepulsid tablet. As shown in the graph, the plasma concentration of the solid dispersed preparations according to the present invention are greatly improved relative to that of the commercially available preparation. These drug concentrations are numerically shown in Table 14, below.
TABLE 14
Plasma Concentration of Cisapride (μg/ml ] in Beagle Dog
Figure imgf000053_0001
As shown in Table 14, the plasma concentration of cisapride is maintained at higher levels when the solid dispersed preparation of the present invention is used than when the conventional preparation.
As described hereinbefore, the solid dispersed preparations of the present invention are improved in the solubility of poorly water-soluble drugs in the gastrointestinal tract, in detail, the releasing of the drugs against the gastric and intestinal juices, resulting in a great increase in the bioavailability of the drugs. In addition, the solid dispersed preparations of the present invention give the pharmaceutical solutions to the problems that the conventional semi-solid or liquid preparations possess, enabling medicinally effective, poorly water- soluble compounds to be formulated, molded and processed, quickly and in an economically favorable manner without use of any organic solvent.
The present invention has been described in an illustrative manner, and it is to be understood the terminology used is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

Claims

WHAT IS CLAIMED IS
1. A solid dispersed preparation for poorly water-soluble drugs, prepared by dissolving or dispersing the drugs in an oil, a fatty acid or a mixture thereof, mixing the solution or dispersion in a water-soluble polyol matrix and drying the mixture.
2. The solid dispersed preparation as set forth in claim 1, wherem the solid dispersed preparation is obtained by pulverizing the dried mixture to give a dispersed powdery preparation .
3. The solid dispersed preparation as set forth m claim 1, wherem the mixture is dried such a way that the mixture is sprayed to pharmaceutically acceptable nuclei to give a dispersed granular preparation.
4. The solid dispersed preparation as set forth in claim 1, wherein the oil, the fatty acid or the mixture thereof is used in a form of an emulsion or a micro emulsion.
5. The solid dispersed preparation as set forth claim 1, wherem the oil is selected from the group comprising -bisabolol, stearyl glycerrhetmate, salicylic acid, tocopheryl acetate, sodium hyaluronate, panthenol, propylene glycol and apple (P rus Mal us ) , propylene glycol and pineapple, ivy { Hedera ha i ϊx ) extract and 1,3-B.G, peach { Prums persica ) leaf extract, hydrolyzed soy flour, wheat { Tri ticum Vulgare) protein, birch { Be t ula a lba ) extract and 1,3-B.G, burdock { Arctium maj us ) extract and 1,3-B.G, liposomes, phosphatidylcholines, glyceryl stearate, captylic/capric triglyceride, cetyl octanolate, isopropyl myristate, 2-ethylene isopelagonate, di-C12- 13 alkyl malate, ceteatyl octanoate, butylene glycol dicaptylate/dicaprate, isononyl isostearate, isostearyl isostearate, coco-captylate/caprate, cetyl octanoate, octyldodecyl myristate, cetyl esters, C10-30 cholesterol/lanosterol ester, hydrogenated castor oil, monoglycerides, diglycerides, triglycerides, beeswax, canaubawax, suctose distearate, PEG-8 beeswax, ceresin, ozokerite, macadamia ternifolia nut oil, hydrogenated hi-erucic acid rape seed oil, olive oil, jojoba oil, hybridsunflower (Helian thus annuus) oil, and dog rose (rosa canina) lips oil.
6. The solid dispersed preparation as set forth in claim 5, wherein the oil is selected from the group comprising mineral oils, squalene, squalane, monoglycerides, diglycerides, triglycerides, medium chain glycerides, myglyol, cremophor, hydrogenated caster oil, corn oil, perilla oil, cotton seed oil and lipid-soluble vitamins.
7. The solid dispersed preparation as set forth in claim 1, wherein the fatty acid is selected from the group comprising oleic acid, cetyl alcohol, stearyl alcohol, stearic acid, myristic acid, linoleic acid and lauric acid.
8. The solid dispersed preparation as set forth claim 7, wherein the fatty acid is selected from the group comprising oleic acid, linoleic acid, and isopropyl myristate.
9. The solid dispersed preparation as set forth in claim 1, wherein the water-soluble polymer matrix is selected from the group comprising polyethylene glycol (PEG) , carbowax and polyvmyl pyrrolidone (PVP) .
10. The solid dispersed preparation as set forth in claim 1, wherein the poorly water-soluble drugs are dissolved and dispersed in the oil, fatty acid or their mixture in the presence of a surfactant.
11. The solid dispersed preparation as set forth in claim 10, wherein the surfactant is selected from the group comprising glyceryl stearate, polysorbate 60, polysorbate 80, sorbitan trioleate, sorbitan sesquioleate, sorbitan stearate, PEG-20 glyceryl isostearate, ceteth-25, PEG-60 , PEG-60 hydrogenated castor oil, nonoxynol-15 , PEG-6-decyl tet radeceth-20, dimethicone copolyol, glyceryl diisostearate , ceteth- 24, cetearyl alcohol, polyoxylethylene nonyphenyl ether , PEG-40 hydrogenated castor oil, cetyl dimethicone copolyol, polyglyceryl-3-methylglucose distearate, PEG-100 stearate, sorbitan isostearate, sodium lauryl glutamate, disodium cocoamphodiacetate, lauric acid diethanolamide, coconut fatty acid diethanolamide, N, N-bis- (2-hydroxy ethyl ) -cocomide, and cocoamidopropyl betain.
12. The solid dispersed preparation as set forth in claim 1, wherein the water-soluble polymeric matrix is used alone or in combination with other water-soluble matrices.
13. The solid dispersed preparation as set forth in claim 12, wherein the other water-soluble matrix is selected from the group comprising gelatin, gum, carbohydrates, celluloses, polyvinyl alcohol, polyacrylic acid, inorganic compounds and their mixtures, hydroxypropylmethylcellulose acetyl succinate, shellac, zein, polyvinyl acetate phthalate, Eudragit L100, Eudragit S100, sodium arginate, and poly-L-lysine .
14. The solid dispersed preparation as set forth in claim 1, wherein the poorly water-soluble drugs are selected from the group comprising ketoconazole, itraconazole and its derivatives, cyclosporine, cisapride, acetaminophen, aspirin, acetylsalicylic acid, indomethacin, naproxen, warfarin, papaverine, thiabendazole, miconazole, cinnarizine, doxorubicin, omeprazole, cholecalciferol, melphalan, nifedipine, digoxin, benzoic acid, tryptophan, tyrosine, phenylalanine, aztreonam, ibuprofen, phenoxymethylpenicillin, thalidomide, methyltestosterone, prochlorperazine, hydrocortisone, dideoxypurine nucleoside, vitamin D2, sulfonamide, sulfonylurea, p-aminobenzoic acid, melatonin, benzylpenicillin, chlorambucil, diazepin, digitoxin, hydrocortisone butyrate, metronidazole benzoate, tolbutamide, prostaglandin E1(PGE1), fludrocortisone, griseofulvin, miconazole nitrate, leukotriene B4 antagonist, propranolol, thephylline, flubiprofen, sodium benzoate, benzoic acid, riboflavin, benzodiazepine, phenobardital, glyburide, sulfadiazine, sulfaethylthiadiazole, sodium diclofenac, aceclofenac, phyniroin, hioridazinehydrochloride, bropirimine, hydrochlorothiazide, fluconazole, acyclovir, bucillamine, ciprofluoxacin, acetyl-L-carnitine, baclofen, sodium alendronate, lovocarnitine, nimodipine or nimodifine, atenolol, provastatin sodium, lovastatin, isotretinoin, etidronate disodium, doxifluridine, fosfomycin calcium, sotepine, epinastine hydrochloride, carvedilol, epinastine hydrochloride, carvedilol, fosinopril, trandolapril, etretinate cap, metergoline, mercaptopurine, vancomycin hydrochloride, cefixime, cefuroxim axetil, dirithramycin, and dadanosin.
15. The solid dispersed preparation as set forth in claim 13, wherein the poorly water-soluble drugs are selected from the group comprising ketoconazole, itraconazole and its derivatives, cisapride, cyclosporine, nifedipine and aceclofenac.
16. Medicines for internal use such as powders, granules, tablets and capsules, prepared using the solid dispersed preparation of claim 1.
PCT/KR1999/000341 1998-06-27 1999-06-28 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof WO2000000179A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46556/99A AU4655699A (en) 1998-06-27 1999-06-28 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1998/24563 1998-06-27
KR19980024563 1998-06-27
KR1019990024437A KR100336090B1 (en) 1998-06-27 1999-06-26 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
KR1999/24437 1999-06-26

Publications (1)

Publication Number Publication Date
WO2000000179A1 true WO2000000179A1 (en) 2000-01-06

Family

ID=26633822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1999/000341 WO2000000179A1 (en) 1998-06-27 1999-06-28 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof

Country Status (3)

Country Link
KR (1) KR100336090B1 (en)
AU (1) AU4655699A (en)
WO (1) WO2000000179A1 (en)

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001991A1 (en) * 1999-07-01 2001-01-11 Merck & Co., Inc. Pharmaceutical tablets
WO2001051029A1 (en) * 2000-01-14 2001-07-19 Laboratoires Des Produits Ethiques Ethypharm Itraconazole composition and production method
WO2001074356A1 (en) * 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
WO2001076561A2 (en) * 2000-04-10 2001-10-18 Novartis Ag Pharmaceutical compositions
WO2001097853A1 (en) * 2000-06-21 2001-12-27 Biochemie Gesellschaft Mbh Improvement of itraconazole bioavailability
WO2001091727A3 (en) * 2000-05-30 2002-05-10 Basf Aktiengesellschaft Self-emulsifying active substance formulation and use of this formulation
EP1239831A1 (en) * 1999-12-23 2002-09-18 F H Faulding & Co. Limited Improved pharmaceutical compositions for poorly soluble drugs
WO2003003999A2 (en) * 2001-07-02 2003-01-16 Elan Corporation, Plc. Delivery of a bioactive material
WO2003004060A1 (en) * 2001-07-03 2003-01-16 Pharm Tech Research, Inc. Compositions and preparation methods for bioavailable oral aceaceclofenac dosage forms
WO2003011258A1 (en) * 2001-07-26 2003-02-13 Cortendo Ab Pharmaceutical formulations comprising ketoconazole
EP1335707A2 (en) * 2000-10-24 2003-08-20 SmithKline Beecham Corporation Novel formulations of carvedilol
WO2003068266A1 (en) * 2002-02-14 2003-08-21 Solvay Pharmaceuticals B.V. Oral solid solution formulation of a poorly water-soluble active substance
WO2004002447A2 (en) * 2002-06-26 2004-01-08 Alza Corporation Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
WO2005032516A1 (en) * 2003-10-09 2005-04-14 Korea United Pharm, Inc Formulation and manufacturing process of self-microemulsified aceclofenac soft capsules
WO2005105041A2 (en) * 2004-04-27 2005-11-10 Formatech, Inc. Methods of enhancing solubility in water of hydrophobic compounds by micellar dispersions
WO2005105039A1 (en) * 2004-05-04 2005-11-10 Boehringer Ingelheim International Gmbh Solid pharmaceutical form comprising an ltb4 antagonist
EP1663231A1 (en) * 2003-09-09 2006-06-07 Hanmi Pharm. Co., Ltd. Oral itraconazole composition which is not affected by ingested food and process for preparing same
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
WO2007138557A2 (en) * 2006-05-30 2007-12-06 Ranbaxy Laboratories Limited Controlled-release multiple unit pharmaceutical compositions
US20080020018A1 (en) * 2004-09-27 2008-01-24 Joey Moodley Combination Products
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
CN100430055C (en) * 2005-11-11 2008-11-05 天津泰普药品科技发展有限公司 Glassiness sosoloid contg. 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazol formic-acid and polyvinyl pyrrolidone and its prepn. method
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
EP1847257A3 (en) * 2006-04-20 2009-11-11 Shin-Etsu Chemical Co., Ltd. Solid preparation comprising enteric solid dispersion
JP2009292834A (en) * 2000-12-05 2009-12-17 Childrens Hospital Los Angeles Pharmaceutical composition of fenretinide having increased bioavailability, and method for using the composition
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7745400B2 (en) 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
EP2216015A1 (en) * 2007-11-02 2010-08-11 Aspion Co., Ltd. Poorly soluble substance-surfactant complex product, and process for production thereof
WO2011139237A1 (en) * 2010-05-05 2011-11-10 Synergy Pharmaceuticals Pte Ltd Composition for the treatment of helicobacter pylori (h. pylori) infectious
EP2347756A3 (en) * 2001-07-06 2012-08-08 Veloxis Pharmaceuticals A/S Controlled agglomeration
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
HRP20040320B1 (en) * 2001-09-10 2012-11-30 Tibotec Pharmaceuticals Ltd. Method for the preparation of hexahydro-furo(2,3-b) furan-3-ol
US8367102B2 (en) * 2000-09-22 2013-02-05 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8563518B2 (en) 2005-07-13 2013-10-22 Allergan, Inc. Cyclosporin compositions
US8591942B2 (en) 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
WO2014100403A1 (en) * 2012-12-19 2014-06-26 Kashiv Pharma, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
US8911777B2 (en) 2007-04-04 2014-12-16 Sigmoid Pharma Limited Pharmaceutical composition of tacrolimus
US8921374B2 (en) 2012-06-21 2014-12-30 Mayne Pharma International Pty Ltd Itraconazole compositions and dosage forms, and methods of using the same
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9023393B2 (en) 2003-08-04 2015-05-05 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
US9107830B2 (en) 1999-11-12 2015-08-18 Abbvie, Inc. Inhibitors of crystallization in a solid dispersion
US9220681B2 (en) 2012-07-05 2015-12-29 Sigmoid Pharma Limited Formulations
US9248191B2 (en) 2003-09-15 2016-02-02 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1469832B2 (en) † 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
WO2016193779A1 (en) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US9821024B2 (en) 2010-11-25 2017-11-21 Sigmoid Pharma Limited Immunomodulatory compositions
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
CN107519496A (en) * 2017-09-19 2017-12-29 沈阳药科大学 A kind of L carnitines amphipathic derivatives and its nanoparticle of modification and application thereof
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10434138B2 (en) 2013-11-08 2019-10-08 Sublimity Therapeutics Limited Formulations
CN110478321A (en) * 2019-09-16 2019-11-22 四川恒通动物制药有限公司 A kind of veterinary drug soluble powder that can be mixed thoroughly with pellet
US10517846B2 (en) * 2016-05-26 2019-12-31 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for treating acne
US10668158B2 (en) * 2015-11-17 2020-06-02 University-Industry Foundation, Yonsei University Sustained-release preparation of poorly soluble drug
US10993987B2 (en) 2014-11-07 2021-05-04 Sublimity Therapeutics Limited Compositions comprising Cyclosporin
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100426346B1 (en) * 2000-11-30 2004-04-08 한국화학연구원 Pharmaceutical compositions for Hypercholesterolemia treatment using of Self Emulsifying drug delivery system
KR100449818B1 (en) * 2001-03-02 2004-09-22 최영욱 Soft capsule or injection formulation containg ibuprofen by smedds
KR100560068B1 (en) * 2002-03-14 2006-03-13 주식회사 태평양 Method for the preparation of oral microcapsule and the oral composition containing the microcapsule prepared by the same
KR100397349B1 (en) * 2002-11-23 2003-09-13 Korea United Pharm Inc Solubilized aceclofenac, soft capsule using the same and manufacturing method thereof
KR100546047B1 (en) * 2003-10-24 2006-01-24 지상철 Sustained-release preparation of dihydropyridine-based compound and preparation method thereof
KR100582604B1 (en) * 2004-06-16 2006-05-23 보람제약주식회사 IBUPROFEN and DEXIBUPROFEN MICRO EMULSION COMPOSITION AND LIQUID MEDICINE and SOFT CAPSULE DRUG THEREOF
KR101631243B1 (en) * 2009-05-13 2016-06-17 신일제약주식회사 Method for preparing novel alendronate emulsion dried product and pharmaceutical composition containing the same
KR101125453B1 (en) * 2010-07-29 2012-03-27 주식회사 대웅제약 Solubilizing Compositions of L-Tryptophan and Pharmaceutical preparation therefrom
WO2013137694A1 (en) * 2012-03-16 2013-09-19 한국콜마 주식회사 Solid matter for water-insoluble material coated with amorphous surfactant containing fatty acid having straight alkyl chain 직쇄 알킬체인을 가진 지방산을 포함하는 무수무복계면물질
KR20170078972A (en) * 2015-12-29 2017-07-10 단국대학교 천안캠퍼스 산학협력단 Pharmaceutical composition comprising cyclosporine
KR101819310B1 (en) 2015-12-29 2018-01-18 단국대학교 천안캠퍼스 산학협력단 Pharmaceutical composition comprising cyclosporine
KR102017619B1 (en) * 2017-12-08 2019-09-04 스킨큐어 주식회사 Composition for Anti-Inflammation Anti-Pruritus, Skin Moisturizing and Skin Suppression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006746A1 (en) * 1988-12-20 1990-06-28 Medicontrol Corporation Heat-dehydrated emulsion compositions
JPH08157362A (en) * 1994-12-06 1996-06-18 Sankyo Co Ltd Production of oily substance-containing solid preparation
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
WO1990006746A1 (en) * 1988-12-20 1990-06-28 Medicontrol Corporation Heat-dehydrated emulsion compositions
JPH08157362A (en) * 1994-12-06 1996-06-18 Sankyo Co Ltd Production of oily substance-containing solid preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JP 08157362 A (SANKYO CO LTD) 18 June 1996 (abstract)(online)(retrieved on 28 October 1999) Retrieved from the Internet:<URL: http://12.espacenet.com/dips/viewer?PN= JP8157362&CY=at&LG=de&DB=EPD>. *

Cited By (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001991A1 (en) * 1999-07-01 2001-01-11 Merck & Co., Inc. Pharmaceutical tablets
US6623755B2 (en) 1999-07-01 2003-09-23 Merck & Co., Inc. Pharmaceutical tablets
US9107830B2 (en) 1999-11-12 2015-08-18 Abbvie, Inc. Inhibitors of crystallization in a solid dispersion
EP1239831A4 (en) * 1999-12-23 2009-07-22 Mayne Pharma Int Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
US8771739B2 (en) 1999-12-23 2014-07-08 Mayne Pharma International Pty Ltd Pharmaceutical compositions for poorly soluble drugs
EP1239831A1 (en) * 1999-12-23 2002-09-18 F H Faulding &amp; Co. Limited Improved pharmaceutical compositions for poorly soluble drugs
JP2003518483A (en) * 1999-12-23 2003-06-10 エフ エイチ フォールディング アンド カンパニー リミテッド Improved pharmaceutical composition for poorly soluble drugs
WO2001051029A1 (en) * 2000-01-14 2001-07-19 Laboratoires Des Produits Ethiques Ethypharm Itraconazole composition and production method
FR2803748A1 (en) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques ITRACONAZOLE COMPOSITION AND PROCESS FOR PREPARATION
WO2001074356A1 (en) * 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
JP2003528914A (en) * 2000-04-03 2003-09-30 エフ．ホフマン−ラ ロシュ アーゲー Concentrated solution of carvedilol
WO2001076561A3 (en) * 2000-04-10 2002-02-21 Novartis Ag Pharmaceutical compositions
EP1767193A3 (en) * 2000-04-10 2009-01-28 Novartis AG Pharmaceutical compositions
JP2003530340A (en) * 2000-04-10 2003-10-14 ノバルティス アクチエンゲゼルシャフト Pharmaceutical composition
WO2001076561A2 (en) * 2000-04-10 2001-10-18 Novartis Ag Pharmaceutical compositions
FR2807658A1 (en) * 2000-04-10 2001-10-19 Novartis Ag PHARMACEUTICAL COMPOSITIONS
JP2003534369A (en) * 2000-05-30 2003-11-18 ビーエーエスエフ アクチェンゲゼルシャフト Self-emulsifying active substance formulation and use of this formulation
WO2001091727A3 (en) * 2000-05-30 2002-05-10 Basf Aktiengesellschaft Self-emulsifying active substance formulation and use of this formulation
WO2001097853A1 (en) * 2000-06-21 2001-12-27 Biochemie Gesellschaft Mbh Improvement of itraconazole bioavailability
US8367102B2 (en) * 2000-09-22 2013-02-05 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
US8952064B2 (en) 2000-09-22 2015-02-10 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
US9089534B2 (en) 2000-09-22 2015-07-28 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
EP1335707A2 (en) * 2000-10-24 2003-08-20 SmithKline Beecham Corporation Novel formulations of carvedilol
EP1335707A4 (en) * 2000-10-24 2005-07-06 Smithkline Beecham Corp Novel formulations of carvedilol
JP2009292834A (en) * 2000-12-05 2009-12-17 Childrens Hospital Los Angeles Pharmaceutical composition of fenretinide having increased bioavailability, and method for using the composition
US7670626B2 (en) 2001-07-02 2010-03-02 Merrion Research Iii Limited Delivery of a bioactive material
WO2003003999A3 (en) * 2001-07-02 2003-06-19 Elan Corp Plc Delivery of a bioactive material
WO2003003999A2 (en) * 2001-07-02 2003-01-16 Elan Corporation, Plc. Delivery of a bioactive material
US8753683B2 (en) 2001-07-02 2014-06-17 Merrion Research Iii Limited Delivery of a bioactive material
WO2003004060A1 (en) * 2001-07-03 2003-01-16 Pharm Tech Research, Inc. Compositions and preparation methods for bioavailable oral aceaceclofenac dosage forms
US8535799B2 (en) 2001-07-06 2013-09-17 Veloxis Pharmaceuticals A/S Controlled agglomeration
US9295653B2 (en) 2001-07-06 2016-03-29 Veloxis Pharmaceuticals A/S Controlled agglomeration
EP2347756A3 (en) * 2001-07-06 2012-08-08 Veloxis Pharmaceuticals A/S Controlled agglomeration
EP1406594B1 (en) * 2001-07-06 2019-06-05 Veloxis Pharmaceuticals A/S Controlled agglomeration
WO2003011258A1 (en) * 2001-07-26 2003-02-13 Cortendo Ab Pharmaceutical formulations comprising ketoconazole
HRP20040320B1 (en) * 2001-09-10 2012-11-30 Tibotec Pharmaceuticals Ltd. Method for the preparation of hexahydro-furo(2,3-b) furan-3-ol
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US10357455B2 (en) 2002-02-01 2019-07-23 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US9486410B2 (en) 2002-02-01 2016-11-08 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
EP1469832B2 (en) † 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AU2003208713B2 (en) * 2002-02-14 2007-10-18 Solvay Pharmaceuticals B.V. Oral solid solution formulation of a poorly water-soluble active substance
AU2003208713B9 (en) * 2002-02-14 2003-09-04 Solvay Pharmaceuticals B.V. Oral solid solution formulation of a poorly water-soluble active substance
WO2003068266A1 (en) * 2002-02-14 2003-08-21 Solvay Pharmaceuticals B.V. Oral solid solution formulation of a poorly water-soluble active substance
WO2004002447A3 (en) * 2002-06-26 2004-06-10 Alza Corp Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2004002447A2 (en) * 2002-06-26 2004-01-08 Alza Corporation Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
USRE47033E1 (en) 2003-08-04 2018-09-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US9023393B2 (en) 2003-08-04 2015-05-05 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US8333990B2 (en) 2003-08-28 2012-12-18 Abbott Laboratories Solid pharmaceutical dosage form
US8399015B2 (en) 2003-08-28 2013-03-19 Abbvie Inc. Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8691878B2 (en) 2003-08-28 2014-04-08 Abbvie Inc. Solid pharmaceutical dosage form
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8309613B2 (en) 2003-08-28 2012-11-13 Abbvie Inc. Solid pharmaceutical dosage form
EP1663231A4 (en) * 2003-09-09 2009-04-29 Hanmi Pharm Ind Co Ltd Oral itraconazole composition which is not affected by ingested food and process for preparing same
EP1663231A1 (en) * 2003-09-09 2006-06-07 Hanmi Pharm. Co., Ltd. Oral itraconazole composition which is not affected by ingested food and process for preparing same
JP2007505103A (en) * 2003-09-09 2007-03-08 ハンミ ファーム． シーオー．， エルティーディー． Itraconazole oral composition not affected by ingested food and drink and method for producing the same
US9248191B2 (en) 2003-09-15 2016-02-02 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
WO2005032516A1 (en) * 2003-10-09 2005-04-14 Korea United Pharm, Inc Formulation and manufacturing process of self-microemulsified aceclofenac soft capsules
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
WO2005105041A3 (en) * 2004-04-27 2006-03-02 Formatech Inc Methods of enhancing solubility in water of hydrophobic compounds by micellar dispersions
WO2005105041A2 (en) * 2004-04-27 2005-11-10 Formatech, Inc. Methods of enhancing solubility in water of hydrophobic compounds by micellar dispersions
US7687458B2 (en) 2004-04-27 2010-03-30 Formatech, Inc. Pharmaceutical compositions of hydrophobic compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
JP2007536299A (en) * 2004-05-04 2007-12-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Solid pharmaceutical form containing LTB4 antagonite
WO2005105039A1 (en) * 2004-05-04 2005-11-10 Boehringer Ingelheim International Gmbh Solid pharmaceutical form comprising an ltb4 antagonist
US20080020018A1 (en) * 2004-09-27 2008-01-24 Joey Moodley Combination Products
US8211855B2 (en) 2005-07-13 2012-07-03 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US10456474B2 (en) 2005-07-13 2019-10-29 Saint Regis Mohawk Tribe Cyclosporin compositions
US9101574B2 (en) 2005-07-13 2015-08-11 Allergan, Inc. Cyclosporin compositions
US8563518B2 (en) 2005-07-13 2013-10-22 Allergan, Inc. Cyclosporin compositions
US8969306B2 (en) 2005-07-13 2015-03-03 Allergan, Inc. Cyclosporin compositions
US8969307B2 (en) 2005-07-13 2015-03-03 Allergan, Inc. Cyclosporin compositions
US8536134B2 (en) 2005-07-13 2013-09-17 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US8575108B2 (en) 2005-07-13 2013-11-05 Allergan, Inc. Cyclosporin compositions
US10507229B2 (en) 2005-07-13 2019-12-17 Saint Regis Mohawk Tribe Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US8906861B2 (en) 2005-07-27 2014-12-09 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US8501174B2 (en) 2005-10-14 2013-08-06 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
CN100430055C (en) * 2005-11-11 2008-11-05 天津泰普药品科技发展有限公司 Glassiness sosoloid contg. 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazol formic-acid and polyvinyl pyrrolidone and its prepn. method
EP1847257A3 (en) * 2006-04-20 2009-11-11 Shin-Etsu Chemical Co., Ltd. Solid preparation comprising enteric solid dispersion
WO2007138557A2 (en) * 2006-05-30 2007-12-06 Ranbaxy Laboratories Limited Controlled-release multiple unit pharmaceutical compositions
WO2007138557A3 (en) * 2006-05-30 2008-02-14 Ranbaxy Lab Ltd Controlled-release multiple unit pharmaceutical compositions
US8911777B2 (en) 2007-04-04 2014-12-16 Sigmoid Pharma Limited Pharmaceutical composition of tacrolimus
US9114071B2 (en) 2007-04-04 2015-08-25 Sigmoid Pharma Limited Oral pharmaceutical composition
US9675558B2 (en) 2007-04-04 2017-06-13 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US10434139B2 (en) 2007-04-04 2019-10-08 Sublimity Therapeutics Limited Oral pharmaceutical composition
US9585844B2 (en) 2007-04-04 2017-03-07 Sigmoid Pharma Limited Oral pharmaceutical composition
US9387179B2 (en) 2007-04-04 2016-07-12 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US10434140B2 (en) 2007-04-04 2019-10-08 Sublimity Therapeutics Limited Pharmaceutical cyclosporin compositions
EP2216015A4 (en) * 2007-11-02 2012-12-19 So Pharmaceutical Corp Poorly soluble substance-surfactant complex product, and process for production thereof
EP2216015A1 (en) * 2007-11-02 2010-08-11 Aspion Co., Ltd. Poorly soluble substance-surfactant complex product, and process for production thereof
US20180264076A1 (en) * 2009-05-18 2018-09-20 Sigmoid Pharma Limited Composition comprising oil drops
US9999651B2 (en) 2009-05-18 2018-06-19 Sigmoid Pharma Limited Composition comprising oil drops
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
US9586978B2 (en) 2009-06-11 2017-03-07 Abbvie Inc. Anti-viral compounds
US8921514B2 (en) 2009-06-11 2014-12-30 Abbvie Inc. Anti-viral compounds
US10028937B2 (en) 2009-06-11 2018-07-24 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US10039754B2 (en) 2009-06-11 2018-08-07 Abbvie Inc. Anti-viral compounds
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US9655846B2 (en) 2009-09-23 2017-05-23 Indu JAVERI Methods for the preparation of liposomes comprising drugs
US9402812B2 (en) 2009-09-23 2016-08-02 Indu JAVERI Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US8591942B2 (en) 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
WO2011139237A1 (en) * 2010-05-05 2011-11-10 Synergy Pharmaceuticals Pte Ltd Composition for the treatment of helicobacter pylori (h. pylori) infectious
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US9821024B2 (en) 2010-11-25 2017-11-21 Sigmoid Pharma Limited Immunomodulatory compositions
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
US8921374B2 (en) 2012-06-21 2014-12-30 Mayne Pharma International Pty Ltd Itraconazole compositions and dosage forms, and methods of using the same
US11638758B2 (en) 2012-06-21 2023-05-02 Mayne Pharma International Pty. Ltd Itraconazole compositions and dosage forms, and methods of using the same
US10806792B2 (en) 2012-06-21 2020-10-20 Mayne Pharma International Pty Ltd. Itraconazole compositions and dosage forms, and methods of using the same
US10463740B2 (en) 2012-06-21 2019-11-05 Mayne Pharma International Pty. Ltd. Itraconazole compositions and dosage forms, and methods of using the same
US9713642B2 (en) 2012-06-21 2017-07-25 Mayne Pharma International Pty. Ltd. Itraconazole compositions and dosage forms, and methods of using the same
US9272046B2 (en) 2012-06-21 2016-03-01 Mayne Pharma International Pty. Ltd. Itraconazole compositions and dosage forms, and methods of using the same
US9220681B2 (en) 2012-07-05 2015-12-29 Sigmoid Pharma Limited Formulations
US9950051B2 (en) 2012-07-05 2018-04-24 Sigmoid Pharma Limited Formulations
CN105007898A (en) * 2012-12-19 2015-10-28 卡希夫制药有限责任公司 Supersaturated stabilized nanoparticles for poorly soluble drugs
WO2014100403A1 (en) * 2012-12-19 2014-06-26 Kashiv Pharma, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
US10500282B2 (en) 2012-12-19 2019-12-10 Kashiv Biosciences, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US10434138B2 (en) 2013-11-08 2019-10-08 Sublimity Therapeutics Limited Formulations
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9744170B2 (en) 2014-01-03 2017-08-29 Abbvie Inc. Solid antiviral dosage forms
US10105365B2 (en) 2014-01-03 2018-10-23 Abbvie Inc. Solid antiviral dosage forms
US10993987B2 (en) 2014-11-07 2021-05-04 Sublimity Therapeutics Limited Compositions comprising Cyclosporin
WO2016193779A1 (en) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
US10668158B2 (en) * 2015-11-17 2020-06-02 University-Industry Foundation, Yonsei University Sustained-release preparation of poorly soluble drug
US10517846B2 (en) * 2016-05-26 2019-12-31 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for treating acne
CN107519496A (en) * 2017-09-19 2017-12-29 沈阳药科大学 A kind of L carnitines amphipathic derivatives and its nanoparticle of modification and application thereof
CN107519496B (en) * 2017-09-19 2019-12-10 沈阳药科大学 L-carnitine amphiphilic derivative, nanoparticle modified by same and application thereof
CN110478321A (en) * 2019-09-16 2019-11-22 四川恒通动物制药有限公司 A kind of veterinary drug soluble powder that can be mixed thoroughly with pellet

Also Published As

Publication number Publication date
AU4655699A (en) 2000-01-17
KR100336090B1 (en) 2002-05-27
KR20000006503A (en) 2000-01-25

Similar Documents

Publication Publication Date Title
WO2000000179A1 (en) Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof
Panigrahi et al. Gelucire: A versatile polymer for modified release drug delivery system
JP5403585B2 (en) Delivery system for active agents
Tran et al. Recent trends of self-emulsifying drug delivery system for enhancing the oral bioavailability of poorly water-soluble drugs
RU2452469C2 (en) Benzimidazolylpyridyl ester compounds
US6306434B1 (en) Pharmaceutical composition comprising cyclosporin solid-state microemulsion
JP6142104B2 (en) Novel oral formulations for tetrapyrrole derivatives
US20020102301A1 (en) Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
TW200800305A (en) Encapsulation of lipid-based formulations in enteric polymers
JP2020534246A (en) Deuterated domperidone compositions, methods, and preparations
KR20110005883A (en) Improved formulations for poorly permeable active pharmaceutical ingredients
WO2006021160A1 (en) Butylbenzene phthalein self-emulsifying drug delivery system, its preparation method and application
Tarate et al. Oral solid self-emulsifying formulations: a patent review
CN103315960A (en) Solid self-microemulsion based on spherical crystallization technique and preparation method thereof
AU2016372683A1 (en) Complexes of celecoxib and its salts and derivatives process for the preparation thereof and pharmaceutical compositions containing them
Guo et al. High oral bioavailability of 2-methoxyestradiol in PEG-PLGA micelles-microspheres for cancer therapy
MX2007007887A (en) Novel galenic system for active principle transport, preparation method and use.
Pi et al. Polymer blends used to develop felodipine-loaded hollow microspheres for improved oral bioavailability
CN101810560B (en) Cyclosporine A polymeric micelles composition
CN101007011B (en) Ginsenoside Rh2 self-emulsifying composition and its preparation method
Kumar et al. Spray Drying as an Effective Method in the Development of Solid Self-Emulsifying Drug Delivery Systems
Chengaiah et al. Self emulsifying drug delivery system: a novel approach for drug delivery
CN102600076A (en) Cyclosporine A solid self-microemulsion particle and preparation method thereof
CN102133192B (en) Candesartan cilexetil lipid nanoparticle solid preparation
Albaidhani et al. Preparation and evaluation of solid supersaturable self-nanoemulsifying drug delivery system of candesartan cilexetil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WA Withdrawal of international application